share_log

開拓藥業-B：截至二零二四年一月三十一日止月份之股份發行人的證券變動月報表

KINTOR PHARMA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

香港交易所 ·  Feb 5 03:31
Summary by Moomoo AI
開拓藥業-B（開拓藥業有限公司）於2024年2月5日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年1月31日的公司股本變動情況。報告顯示，公司的法定/註冊股本及已發行股份在本月內無增減，維持在700,000,000股，每股面值0.0001美元，總股本為70,000美元。此外，報告中確認了公司在本月內發行的證券已獲得董事會的正式授權，並符合香港聯合交易所有限公司證券上市規則的所有要求。開拓藥業-B為一家在開曼群島註冊成立的有限公司，由主席、執行董事及行政總裁童友之呈交本報表。
開拓藥業-B（開拓藥業有限公司）於2024年2月5日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年1月31日的公司股本變動情況。報告顯示，公司的法定/註冊股本及已發行股份在本月內無增減，維持在700,000,000股，每股面值0.0001美元，總股本為70,000美元。此外，報告中確認了公司在本月內發行的證券已獲得董事會的正式授權，並符合香港聯合交易所有限公司證券上市規則的所有要求。開拓藥業-B為一家在開曼群島註冊成立的有限公司，由主席、執行董事及行政總裁童友之呈交本報表。
APEX PHARMACEUTICALS - B (KAITOU PHARMACEUTICALS CO., LTD.) SUBMITTED ITS LATEST MONTHLY STATEMENT OF SECURITIES CHANGES TO HONG KONG TRADING AND SETTLEMENT LIMITED ON FEBRUARY 5, 2024, REPORTING CHANGES IN THE COMPANY'S SHARE CAPITAL AS OF 31 JANUARY 2024. The report showed that the company's regulated/registered share capital and issued shares remained unchanged during the month, remaining at 700,000,000 shares with a face value of $0.0001 per share and a total share capital of $70,000. In addition, the report confirms that the securities issued by the company during this month have been formally authorized by the Board of Directors and comply with all the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited. Discovery Pharmaceuticals-B is a limited company incorporated in the Cayman Islands, presented this report by the Chairman, Executive Director and Chief Executive Officer, Tofu Yui.
APEX PHARMACEUTICALS - B (KAITOU PHARMACEUTICALS CO., LTD.) SUBMITTED ITS LATEST MONTHLY STATEMENT OF SECURITIES CHANGES TO HONG KONG TRADING AND SETTLEMENT LIMITED ON FEBRUARY 5, 2024, REPORTING CHANGES IN THE COMPANY'S SHARE CAPITAL AS OF 31 JANUARY 2024. The report showed that the company's regulated/registered share capital and issued shares remained unchanged during the month, remaining at 700,000,000 shares with a face value of $0.0001 per share and a total share capital of $70,000. In addition, the report confirms that the securities issued by the company during this month have been formally authorized by the Board of Directors and comply with all the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited. Discovery Pharmaceuticals-B is a limited company incorporated in the Cayman Islands, presented this report by the Chairman, Executive Director and Chief Executive Officer, Tofu Yui.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more